Patient-reported outcomes
Post-hoc analysis: PSSD signs and symptoms diary outcomes with SOTYKTU vs. apremilast1,2
This is a post-hoc analysis and the results for individual subgroups are not powered to draw meaningful conclusions and should therefore be interpreted with caution.
Week 16 in PSO-1: mean change from baseline in signs and symptoms (PSSD) of psoriasis vs. apremilast1
Adapted from SOTYKTU SmPC.
PSO-1: SOTYKTU (n=306); apremilast (n=158).1
Pinch & zoom to explore
PSSD symptoms
- Itch
- Burning
- Pain
- Stinging
- Skin tightness
PSSD-signs
- Dryness
- Redness
- Scaling
- Shedding/flaking
- Cracking
- Bleeding
Bars represent standard error of means.
The PSSD is a patient-reported instrument that assesses the severity of 5 symptoms (burning, itch, pain, skin tightness, stinging) and 6 signs (bleeding, cracking, dryness, redness, scaling, shedding or flaking) on a numerical scale ranging from 0 (absent) to 10 (worst imaginable). Psoriasis symptom and sign summary scores (0–100) were derived based on average scores for the individual symptoms and signs domains.
PSSD, Psoriasis Symptoms and Signs Diary; SE, standard error; SmPC, Summary of Product Characteristics.
Post-hoc analysis: Dermatology Life Quality Index outcomes with SOTYKTU vs. apremilast1,3
This is a post-hoc analysis and the results for individual subgroups are not powered to draw meaningful conclusions and should therefore be interpreted with caution.
Week 24 in PSO-1, percentage of patients achieving DLQI 0/11,3
PSO-1
Adapted from Augustin M et al. 2022.
PSO-1: SOTYKTU (n=322); apremilast (n=161), placebo (n=160).1
Pinch & zoom to explore
DLQI 0/1 score of 0 or 1, no impact on quality of life.
DLQI, Dermatology Life Quality Index.
References
- SOTYKTU. Summary of Product Characteristics.
- Armstrong A et al. J Am Acad Dermatol. 2023;88(1):29–39. Plus supplementary material.
- Augustin M et al. Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: results from the phase 3 POETYK PSO-1 and PSO-2 trials. Presented at the American Academy of Dermatology (AAD) Annual Meeting; March 25—29, 2022. Poster: 35205.